Recently published review papers on diabetes and CNS disorders highlight the importance of DYRK inhibitors in the therapy of cancer and neurological disorders [17,18,19] and suggest the directions in the design and development of small-molecule inhibitors (Figure 1) [12,20,21,22,23]. Here, DYRK1A is linked to cancer.